Substituted indolo 4,3 FG quinolines useful for treating migraine
    1.
    发明授权
    Substituted indolo 4,3 FG quinolines useful for treating migraine 有权
    取代吲哚4,3吡啶喹啉可用于治疗偏头痛

    公开(公告)号:US08710092B2

    公开(公告)日:2014-04-29

    申请号:US12978314

    申请日:2010-12-23

    IPC分类号: A61K31/40

    CPC分类号: C07D519/02 C07D457/04

    摘要: Provided herein are substituted indolo[4,3-fg]quinolines of Formula (I) and (II) where R1-R6 and R13 are as defined in the specification and pharmaceutical compositions thereof which are useful in treating, preventing, or ameliorating a variety of medical disorders such as, for example, migraine. In other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and or 5-HT1B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of regulating serotonin transport using the compounds and compositions disclosed herein.

    摘要翻译: 本文提供了式(I)和(II)的取代的吲哚并[4,3-f]喹啉,其中R 1 -R 6和R 13如说明书及其药物组合物中所定义,其可用于治疗,预防或改善品种 的医学病症,例如偏头痛。 在其它实施方案中,本文提供了使用本文公开的化合物和组合物来激发受体例如5-HT1D和/或5-HT1B受体的方法。 在其它实施方案中,本文提供了使用本文公开的化合物和组合物拮抗或抑制受体例如5-HT 2B受体的活性的方法。 在其它实施方案中,本文提供了使用本文公开的化合物和组合物调节5-羟色胺转运的方法。

    NOVEL ERGOLINE ANALOGS
    2.
    发明申请
    NOVEL ERGOLINE ANALOGS 有权
    新的胆固醇类似物

    公开(公告)号:US20110152280A1

    公开(公告)日:2011-06-23

    申请号:US12978314

    申请日:2010-12-23

    CPC分类号: C07D519/02 C07D457/04

    摘要: Provided herein are novel ergoline derivatives and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and or 5-HT1B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of regulating serotonin transport using the compounds and compositions disclosed herein.

    摘要翻译: 本文提供了新的麦角灵衍生物及其药物组合物。 在其它实施方案中,本文提供的是使用本文公开的化合物和组合物治疗,预防或改善各种医学病症例如偏头痛的方法。 在其它实施方案中,本文提供了使用本文公开的化合物和组合物来激发受体例如5-HT1D和/或5-HT1B受体的方法。 在其它实施方案中,本文提供了使用本文公开的化合物和组合物拮抗或抑制受体例如5-HT 2B受体的活性的方法。 在其它实施方案中,本文提供了使用本文公开的化合物和组合物调节5-羟色胺转运的方法。